News AbbVie Inc. BOERSE MUENCHEN

Equities

4AB

US00287Y1091

Market Closed - BOERSE MUENCHEN Other stock markets 01:29:44 29/06/2024 am IST			5-day change	1st Jan Change
160.3 ^EUR	+1.42%		+0.24%	+14.72%

28/06	Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU	MT
28/06	AbbVie, Genmab Receive Positive European Opinion on Marketing Authorization for Possible Lymphoma Treatment	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AbbVie - Introducing Alle Payment Plans, Powered by Cherry	28/06	AQ
Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU	28/06	MT
AbbVie, Genmab Receive Positive European Opinion on Marketing Authorization for Possible Lymphoma Treatment	28/06	MT
AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma	28/06	PR
AbbVie Receives Positive CHMP Opinion for Epcoritamab for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma	28/06	CI
Health Care Stocks Fall With Broad Market -- Health Care Roundup	28/06	DJ
Sector Update: Health Care Stocks Slipping Late Afternoon	28/06	MT
Sector Update: Health Care Stocks Decline in Afternoon Trading	27/06	MT
AbbVie: acquisition of Celsius for $250 million	27/06	CF
AbbVie Buys Celsius Therapeutics for $250 Million	27/06	DJ
AbbVie Buys Celsius Therapeutics for $250 million	27/06	MT
AbbVie Buys Celsius Therapeutics for $250 million	27/06	MT
AbbVie Acquires Celsius Therapeutics in $250 Million Cash Deal	27/06	MT
AbbVie Acquires Celsius Therapeutics	27/06	PR
AbbVie - U.S. Food and Drug Administration Grants Second Approval for EPKINLY to Treat Patients with Relapsed or Refractory Follicular Lymphoma	27/06	AQ
Introducing Allē Payment Plans, Powered by Cherry	27/06	PR
Nxera Pharma Co Achieves Key R&D Milestone in Collaboration with AbbVie; Secures $10 Million Payment	27/06	MT
Nxera Pharma Co., Ltd. Receives USD 10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone	27/06	CI
U.S. Food and Drug Administration Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma	27/06	PR
U.S. Food and Drug Administration Grants Second Approval for AbbVie's EPKINLY (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma	27/06	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News AbbVie Inc. BOERSE MUENCHEN

Equities

4AB

US00287Y1091

Summary

Filters